- Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Rebif; Other: other disease modifying therapies (DMT)
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Recruiting - verified May 2012 - Condition: Relapsing Multiple Sclerosis
Intervention:
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Enrolling by invitation - verified May 2012 - Condition: Rotavirus Gastroenteritis
Interventions: Biological: RotaTeq™ experimental formulation; Biological: RotaTeq™ existing formulation
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Conditions: Herpes Zoster; Shingles
Intervention: Biological: ZOSTAVAX™
Sponsors: Merck; Merck; Kaiser Permanente
Not yet recruiting - verified May 2012 - Condition: Hyperlipidemia
Intervention: Drug: Sitagliptin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Merck Frosst Canada Ltd.
Not yet recruiting - verified April 2012 - Condition: HIV
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Merck
Not yet recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: MK-2748; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Conditions: Hypertension; Isolated Systolic Hypertension (ISH)
Interventions: Drug: MK-8150 2.0 mg; Drug: MK-8150 10 mg; Drug: MK-8150 40 mg; Drug: MK-8150 90 mg; Drug: MK-8150 5.0 mg; Drug: MK-8150 20 mg; Drug: MK-8150 60 mg; Drug: MK-8150 120 mg; Drug: MK-8150 160 mg; Drug: MK-8150 320 mg; Drug: MK-8150 600 mg; Drug: MK-8150 900 mg; Drug: MK-8150 1200 mg; Drug: Placebo for MK-8150
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck Quimica Argentina S.A.I.C
Not yet recruiting - verified April 2012 - Condition: Dyslipidemia
Interventions: Drug: Ezetimibe/simvastatin; Drug: Other Statin
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Fosaprepitant Placebo; Drug: Dexamethasone 12 mg; Drug: Dexamethasone 20 mg; Drug: Ondansetron; Drug: Rescue Therapy; Drug: Ondansetron; Drug: Dexamethasone Placebo; Drug: Ondansetron Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress DisorderCondition: Posttraumatic Stress Disorder
Intervention: Drug: Adjunctive asenapine
Sponsors: Tuscaloosa Research & Education Advancement Corporation; Lori Davis, MD; Merck
Not yet recruiting - verified April 2012 - Conditions: Hypercholesterolemia, Familial; Heterozygous Familial Hypercholesterolemia
Interventions: Drug: MK-0524A; Drug: MK-0524A
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Saxagliptin; Drug: Vildagliptin; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Hepatitis C
Intervention: Drug: Boceprevir
Sponsors: University of Calgary; University of Calgary; Merck
Not yet recruiting - verified April 2012 - Condition: Aortic Stenosis
Interventions: Drug: bisoprolol; Drug: placebo
Sponsors: Asan Medical Center; Asan Medical Center; Merck
Not yet recruiting - verified April 2012 - Condition: Rhinitis, Allergic, Perennial
Interventions: Drug: Montelukast to placebo; Drug: Placebo to montelukast
Sponsors: CHA University; CHA University; Merck
Not yet recruiting - verified March 2012 - Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: MK-8457 100 mg; Drug: MK-8457 100 mg; Drug: Dose-Matched Placebo; Drug: MK-8457 200 mg; Drug: MK-8457 25 mg; Drug: MK-8457
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Hypercholesterolaemia
Interventions: Drug: 10mg Ezetimibe; Drug: 10 mg Ezetimibe - wash out period
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Human Papilloma Virus Infection
Intervention:
Sponsors: Merck; Merck
Active, not recruiting - verified April 2012 - Condition: Herpes Zoster
Intervention: Biological: Zostavax
Sponsors: University of Sydney; University of Sydney; South West Sydney Local Health District; Merck
Active, not recruiting - verified April 2012 - Condition: Supratentorial Newly Diagnosed Inoperable Gliobastoma
Interventions: Drug: Drug (including placebo); Other: Standard therapy
Sponsors: Merck KGaA; Merck KGaA
Not yet recruiting - verified March 2012 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck S.A. de C.V., Mexico
Not yet recruiting - verified March 2012 - Conditions: Patient Compliance; Health Knowledge, Attitudes, Practice
Intervention: Procedure: Electronic Message
Sponsors: East Carolina University; East Carolina University; Merck
Recruiting - verified March 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: MK-8325; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/metformin XR; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Heart Failure
Interventions: Drug: MK-7145; Drug: Placebo for MK-7145; Drug: Furosemide
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified March 2012 - Condition: Osteoarthritis of the Knee
Interventions: Drug: Etoricoxib 30 mg; Drug: Celecoxib 200 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Osteoporosis; Postmenopausal Osteoporosis
Interventions: Drug: Odanacatib; Drug: Alendronate; Other: Placebo (odanacatib); Dietary Supplement: Cholecalciferol (Vitamin D3); Dietary Supplement: Calcium carbonate; Other: Placebo (alendronate)
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Conditions: Perennial Allergic Rhinitis; Seasonal Allergic Rhinitis
Intervention: Biological: Allergen Immunotherapy
Sponsors: Merck; Merck
Active, not recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Intervention: Drug: Temozolomide
Sponsors: Stanford University; Stanford University; Merck
Not yet recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Metformin; Drug: Metformin; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia; Adenocarcinoma in Situ
Intervention: Biological: V501
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Hepatitis C; Hypertension
Interventions: Drug: Amlodipine; Drug: Diltiazem
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Merck
Not yet recruiting - verified March 2012 - Conditions: Female Infertility Due to Nonimplantation of Ovum; Complications Associated With Artificial Fertilization
Interventions: Drug: Pergoveris in long protocol with GnRH agonist; Drug: Pergoveris in GnRH antagonist protocol
Sponsors: University of Basel; University of Basel; Merck Serono International SA
Not yet recruiting - verified March 2012 - Condition: Allergic Rhinoconjunctivitis
Intervention:
Sponsors: Merck; Merck
Recruiting - verified March 2012 - Condition: Hepatitis
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Conditions: Herpes Zoster; Shingles
Intervention: Biological: Zoster Vaccine Live
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone; Drug: thalidomide, cyclophosphamide, dexamethasone; Drug: lenalidomide, cyclophosphamide, dexamethasone; Drug: thalidomide, cyclophosphamide, dexamethasone; Drug: bortezomib, cyclophosphamide, dexamethasone; Drug: lenalidomide maintenance; Drug: lenalidomide plus vorinostat maintenance
Sponsors: University of Leeds; University of Leeds; Celgene Corporation; Merck
Recruiting - verified March 2012 - Conditions: Measles; Mumps; Rubella; Varicella
Interventions: Biological: MMRV (AMP); Biological: MMRV (2006 process)
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males (MK-8742-002)Condition: Hepatitis, Viral, Human
Interventions: Drug: MK-8742; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Finasteride (MK-906); Drug: Tamsulosin; Other: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified March 2012 - Conditions: Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: aprepitant; Drug: gemcitabine hydrochloride; Drug: capecitabine; Drug: fluorouracil; Procedure: radiation therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: nausea and vomiting therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI); Merck
Active, not recruiting - verified February 2012 - Conditions: HPV Vaccine Attitudes; HPV Vaccine Intention
Intervention:
Sponsors: Indiana University; Indiana University; Merck
Not yet recruiting - verified February 2012 - Condition: Acute Myeloid Leukemia
Intervention: Drug: sorafenib, vorinostat and bortezomib
Sponsors: Indiana University; Indiana University; Millennium Pharmaceuticals, Inc.; Bayer; Merck
Recruiting - verified February 2012 - Conditions: Hyperlipoproteinemia Type II; Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib; Drug: Placebo for Anacetrapib
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Osteoarthritis
Intervention:
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Conditions: Herpes Zoster; Shingles
Intervention: Biological: Zoster Vaccine Live
Sponsors: Merck; Merck
Not yet recruiting - verified February 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Peg-Interferon; Procedure: Liver Samples from FNA; Procedure: Liver Samples from CNB; Procedure: Blood Samples; Drug: Ribavarin; Drug: 800 mg MK-5172; Drug: 100 mg MK-5172; Procedure: Liver samples from CNB and FNA
Sponsors: Merck; Merck
Not yet recruiting - verified March 2012 - Condition: Multiple Sclerosis
Interventions: Drug: IFN beta 1 a + curcumin (BCM 95); Drug: IFN beta-1a + placebo
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.P.A., Italy
Not yet recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: Famotidine; Drug: Pepcid
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Conditions: Colorectal Cancer; Steatohepatitis
Intervention: Drug: Metformin/Placebo
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Merck Gesellschaft mbH, Austria
Recruiting - verified April 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Female Genital Warts
Intervention:
Sponsors: BEMFAM-Bem Estar Familiar; BEMFAM-Bem Estar Familiar; Merck
Not yet recruiting - verified January 2012 - Condition: Clostridium Difficile Infection
Interventions: Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Bisoprolol; Drug: Metoprolol
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Co., Ltd., China
Not yet recruiting - verified January 2012 - Conditions: Migraine; Headache
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified March 2012 - Conditions: Hepatitis C; HCV
Intervention:
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Recruiting - verified January 2012 - Condition: Renal Insufficiency
Intervention: Drug: MK-0822
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatic Insufficiency
Intervention: Drug: Single Dose MK-0822
Sponsors: Merck; Merck
Completed - verified May 2012 - Condition: Rectal Cancer
Interventions: Other: Chemoradiation Therapy; Drug: Cyclophosphamide; Biological: L-BLP25; Other: Chemoradiation Therapy; Biological: L-BLP25; Other: Chemoradiation Therapy
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified January 2012 - Condition: Renal Impairment
Interventions: Drug: cilengitide 2000mg; Drug: cilengitide 2000mg; Drug: cilengitide 2000mg; Drug: cilengitide 1000mg; Drug: cilengitide > 1000mg and up to 2000mg
Sponsors: Merck KGaA; Merck KGaA
Completed - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Januvia (Sitagliptin phosphate); Other: Placebo
Sponsors: New York Obesity and Nutrition Research Center; Blandine Laferrere, MD; Merck
Not yet recruiting - verified January 2012 - Condition: Gliomas
Interventions: Drug: Cilengitide; Drug: Temozolomide
Sponsors: Martin-Luther-Universität Halle-Wittenberg; Martin-Luther-Universität Halle-Wittenberg; Merck KGaA
Recruiting - verified January 2012 - Condition: Hormone Levels (Progesterone)
Interventions: Drug: hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase; Drug: hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase; Drug: LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase; Drug: vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase
Sponsors: Regionshospitalet Viborg, Skive; Regionshospitalet Viborg, Skive
Not yet recruiting - verified January 2012 - Condition: Intra-abdominal Infections
Interventions: Drug: MK-7655 250 mg with imipenem/cilastatin; Drug: MK-7655 125 mg with imipenem/cilastatin; Drug: imipenem/cilastatin with placebo; Drug: Matching placebo to MK-7655
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus Type 2
Interventions: Drug: Glucophage; Drug: Glucophage
Sponsors: Merck KGaA; Merck KGaA; Merck, S.L., Spain
Not yet recruiting - verified January 2012 - Conditions: Statin Therapy; Adherence
Intervention: Behavioral: CPATCH intervention to support statin adherence
Sponsors: University of Saskatchewan; University of Saskatchewan; Saskatchewan Ministry of Health; Merck Frosst Canada Ltd.
Active, not recruiting - verified January 2012 - Conditions: Complicated Urinary Tract Infections,; Pyelonephritis
Interventions: Drug: MK-7655 250 mg with imipenem/cilastatin; Drug: MK-7655 125 mg with imipenem/cilastatin; Drug: imipenem/cilastatin with placebo; Drug: Matching placebo to MK-7655
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Conditions: Herpes Zoster; Shingles
Interventions: Biological: Zoster Vaccine Live (AMP); Biological: Zoster Vaccine Live
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Pneumococcal Infections
Interventions: Biological: Pneumococcal Conjugate Vaccine (V114); Biological: Pneumococcal Polysaccharide Vaccine; Biological: Pneumococcal 13-Valent Conjugate Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Infertility; Fertility; Follicle Stimulating Hormone Deficiency
Interventions: Drug: Lutropin alfa; Drug: Lutropin alpha
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Middle East FZ LLC
Not yet recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalinomide and Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Merck Sharp & Dohme Corp., Inc.
Recruiting - verified December 2011 - Conditions: Overactive Bladder; Overactive Urinary Bladder
Interventions: Drug: MK-4618; Drug: Tolterodine ER; Drug: MK-1468 and Tolterodine ER; Other: Placebo (MK-4618); Other: Placebo (Tolterodine ER); Drug: Prophylactic Antibiotic
Sponsors: Merck; Merck
Recruiting - verified February 2012 - Condition: Hepatocellular Carcinoma
Interventions: Procedure: MRI; Procedure: Pathology; Procedure: Blood Samples; Procedure: Blood Samples
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Asthma
Intervention:
Sponsors: Capital Institute of Pediatrics, China; Capital Institute of Pediatrics, China; Merck
Recruiting - verified December 2011 - Condition: Human Papillomavirus
Interventions: Other: HPV Vaccine and Disease Education; Other: Reduction of barriers; Other: Survey
Sponsors: Lake Cumberland District Health Department; Lake Cumberland District Health Department; Merck
Not yet recruiting - verified February 2012 - Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Merck
Not yet recruiting - verified December 2011 - Condition: Melanoma
Interventions: Drug: Sylatron; Drug: Yervoy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified March 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Ezetimibe; Drug: Nutraceuticals
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified December 2011 - Conditions: Invasive Pulmonary Aspergillosis; Chronic Obstructive Pulmonary Disease
Intervention: Drug: caspofungin
Sponsors: The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University; Merck
Recruiting - verified March 2012 - Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Vorinostat; Drug: Bortezomib; Drug: pegylated liposomal doxorubicin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Merck
Withdrawn - verified May 2012 - Conditions: Diabetes Mellitus; Type 2 Diabetes
Interventions: Drug: Sitagliptin; Drug: Metformin; Drug: Placebo to sitagliptin; Drug: Placebo to metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: GH Deficiency (GHD); Growth Retardation
Interventions: Drug: Somatropin; Drug: Somatropin
Sponsors: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.; L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
Not yet recruiting - verified December 2011 - Condition: Sexual Transmission of Infection
Interventions: Biological: Gardasil Vaccine; Biological: Placebo Vaccine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Not yet recruiting - verified May 2012 - Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012 - Condition: Fungal Infection
Intervention:
Sponsors: Ruijin Hospital; Ruijin Hospital; Merck
Enrolling by invitation - verified December 2011 - Conditions: Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance
Intervention: Drug: Dexamethasone
Sponsors: University of Vermont; University of Vermont; Merck
Not yet recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Bacterial Infections; Virus Diseases
Interventions: Biological: V419; Biological: Rotavirus vaccine; Biological: Prevenar 13; Biological: INFANRIX hexa
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Condition: Dengue
Interventions: Biological: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant; Biological: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant; Biological: Medium-dose V180 (non-adjuvanted); Biological: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant; Biological: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant; Biological: Medium-dose V180 with Alhydrogel™ adjuvant; Biological: High-dose V180 (non-adjuvanted); Biological: High-dose V180 with low-dose ISCOMATRIX™ adjuvant; Biological: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant; Biological: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant; Biological: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant; Biological: High-dose V180 with high-dose ISCOMATRIX™ adjuvant; Biological: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: Sitagliptin / Metformin; Drug: Placebo to Metformin; Drug: Placebo to Sitagliptin / Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Herpes Zoster
Intervention: Behavioral: Education
Sponsors: New York University School of Medicine; New York University School of Medicine; Merck
Completed - verified March 2012 - Condition: Systemic Lupus Erythematosus
Intervention: Drug: Zostavax vaccine
Sponsors: Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation
Recruiting - verified November 2011 - Conditions: Polycystic Ovary Syndrome; Normal Volunteers
Intervention: Drug: IVF Antagonist Protocol
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Not yet recruiting - verified December 2011 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Merck; Merck
Active, not recruiting - verified November 2011 - Condition: Osteoporosis
Intervention:
Sponsors: China-Japan Friendship Hospital; China-Japan Friendship Hospital; Merck
Not yet recruiting - verified November 2011 - Condition: Contraception
Intervention:
Sponsors: Center for Epidemiology and Health Research, Germany; Center for Epidemiology and Health Research, Germany; Merck
Recruiting - verified November 2011 - Conditions: Viral Gastroenteritis Due to Rotavirus; Gastroenteritis
Intervention:
Sponsors: Women's and Children's Hospital, Australia; Associate Professor Helen Marshall; Merck
Active, not recruiting - verified November 2011 - Condition: Human Papillomavirus (HPV) Type 16/18 Infections
Interventions: Biological: Cervarix; Biological: Gardasil; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: MK-1439; Drug: Placebo
Sponsors: Merck; Merck
Completed - verified May 2012 - Conditions: Crohn's Disease; Ulcerative Colitis
Intervention:
Sponsors: Hvidovre University Hospital; Hvidovre University Hospital; Ferring Pharmaceuticals; Merck
Enrolling by invitation - verified November 2011 - Condition: Nasal Allergies
Intervention: Other: allergen challenge
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Merck
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Intervention:
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Antibiotics
Interventions: Other: Probiotic; Other: Probiotic; Other: Probiotic
Sponsors: Eurofarma Laboratorios S.A.; Eurofarma Laboratorios S.A.
Not yet recruiting - verified October 2011 - Condition: Prostate Cancer
Interventions: Drug: Radiation; Drug: Androgen Deprivation Therapy (ADT); Other: Standard of care; Drug: L-BLP25
Sponsors: EMD Serono; EMD Serono
Recruiting - verified December 2011 - Condition: Crohn Disease
Interventions: Other: Endoscopy; Other: Endoscopy
Sponsors: University of Bern; University of Bern; University Hospital, Basel, Switzerland; University of Lausanne Hospitals; Swiss IBD Cohort Study; MSD Merck Sharp & Dohme AG
Active, not recruiting - verified November 2011 - Condition: Hepatitis B
Interventions: Biological: 2XP HEPTAVAX-II; Biological: 1XP HEPTAVAX-II
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Conditions: HCV Infections; Gastric Acid-related Disorders
Interventions: Drug: boceprevir; Drug: Omeprazole
Sponsors: Radboud University; Radboud University; Merck
Recruiting - verified November 2011 - Condition: Dysmenorrhea
Interventions: Drug: Etoricoxib; Drug: Ibuprofen; Drug: Placebo to etoricoxib; Drug: Placebo to ibuprofen
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Conditions: Glaucoma; Quality of Life
Intervention:
Sponsors: Wills Eye; Wills Eye; Merck
Recruiting - verified November 2011 - Conditions: Inflammatory Bowel Disease; Colorectal Cancer
Intervention:
Sponsors: UMC Utrecht; UMC Utrecht; Merck; Ferring Pharmaceuticals
Recruiting - verified October 2011 - Condition: Solid Tumors
Intervention: Drug: MK-8242
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Herpes Zoster
Intervention: Biological: V212
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Condition: Graves´ Disease
Interventions: Drug: Diclofenac; Drug: Methimazole; Drug: L-thyroxin; Drug: Propranolol; Drug: Metoprolol
Sponsors: Region Skane; Mikael Lantz
Recruiting - verified October 2011 - Condition: Vitamin D Deficiency
Interventions: Dietary Supplement: cholecalciferol; Dietary Supplement: Placebo
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Merck
Not yet recruiting - verified November 2011 - Condition: Allergic Rhinitis
Intervention: Other: Swab of vestibule and middle meatus of nose
Sponsors: University of Chicago; University of Chicago; Merck
Active, not recruiting - verified October 2011 - Conditions: Obesity; Insulin Resistance
Interventions: Dietary Supplement: A dietary supplement together with a hypocaloric diet; Dietary Supplement: A placebo together with a hypocaloric diet
Sponsors: Coordinación de Investigación en Salud, Mexico; Coordinación de Investigación en Salud, Mexico
Not yet recruiting - verified October 2011 - Conditions: Hypogonadism; Osteopenia; Osteoporosis
Interventions: Drug: Testosterone; Drug: Alendronate; Drug: Placebo Alendronate; Drug: Placebo Testosterone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Endo Pharmaceuticals; Merck
Recruiting - verified March 2012 - Condition: Colorectal Cancer (CRC)
Intervention: Drug: Cetuximab
Sponsors: Merck KGaA; Merck KGaA; Merck, S.L., Spain
Recruiting - verified October 2011 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Golimumab; Drug: Placebo
Sponsors: Schering-Plough; Schering-Plough; Johnson & Johnson
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Condition: Human Papilloma Virus
Intervention: Behavioral: Health Education Session
Sponsors: MEE Productions, Inc.; MEE Productions, Inc.; Thomas Jefferson University
Not yet recruiting - verified October 2011 - Condition: Rosacea
Interventions: Drug: Laropiprant; Drug: Placebo for Laropiprant
Sponsors: Merck; Merck
Completed - verified May 2012 - Conditions: HCV Infection; Liver Cirrhosis, Experimental
Interventions: Drug: Boceprevir; Biological: Peg-Interferon α-2b or Peg-Interferon α-2a; Drug: Ribavirin
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis; Merck
Recruiting - verified February 2012 - Condition: Schizophrenia
Interventions: Drug: Asenapine 10 mg once daily in the evening; Drug: Asenapine 5 mg twice daily
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012 - Condition: Low Grade Glioma
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Merck
Recruiting - verified October 2011 - Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012 - Conditions: HIV Infection; Endothelial Dysfunction
Intervention: Drug: raltegravir
Sponsors: UMC Utrecht; UMC Utrecht; Merck
Recruiting - verified February 2012 - Condition: Asthma
Intervention:
Sponsors: Sociedad Española de Neumología y Cirugía Torácica; Sociedad Española de Neumología y Cirugía Torácica; Merck
Recruiting - verified October 2011 - Conditions: Women's Health; HIV Infection; Genital Diseases, Female
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified October 2011 - Conditions: Chronic Hepatitis C; Menopause
Intervention: Drug: Pegylated Interferon, Ribavirin, Boceprevir
Sponsors: University of Modena and Reggio Emilia; University of Modena and Reggio Emilia; Merck
Not yet recruiting - verified October 2011 - Conditions: Human Immunodeficiency Virus (HIV); HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; St Vincent's Hospital, Sydney; Merck
Not yet recruiting - verified October 2011 - Condition: Hypertension
Interventions: Drug: MK-8457; Drug: Placebo for MK-8457
Sponsors: Merck; Merck
Completed - verified April 2012 - Condition: Growth Disorders
Intervention: Device: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.P.A., Italy
Not yet recruiting - verified March 2012 - Conditions: HIV-1 Infection; Chronic Renal Insufficiency
Intervention: Drug: Raltegravir
Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); Merck
Recruiting - verified April 2012 - Condition: Growth Disorders
Intervention: Device: easypod ™
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Co., Ltd., China
Recruiting - verified April 2012 - Conditions: Human Papillomavirus; HIV-1 Infection
Intervention: Biological: Gardasil vaccine
Sponsors: Kenyatta National Hospital; Nelly R. Mugo; University of Washington; Merck
Not yet recruiting - verified October 2011 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Sitagliptin
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Merck
Not yet recruiting - verified October 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: MK-5172; Drug: Placebo to MK-5172; Drug: Peginterferon alfa-2b (Peg-IFN); Drug: Ribavirin (RBV)
Sponsors: Merck; Merck
Terminated - verified May 2012 - Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Early combination therapy; Drug: Delayed combination therapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011 - Condition: Osteoporosis
Intervention: Drug: MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Antifungal Therapy
Intervention: Other: it is a retrospective study, hence no active intervention
Sponsors: Fortis Hospital, India; Fortis Hospital, India; Merck
Active, not recruiting - verified September 2011 - Condition: Bleeding
Interventions: Drug: Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon); Drug: Etonogestrel 68 mg subdermal implant
Sponsors: VL-Medi Oy; VL-Medi Oy; Merck
Not yet recruiting - verified September 2011 - Condition: Dyslipidemia
Intervention:
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Migraine Disorders
Interventions: Drug: Non-steroidal anti-inflammatory drug (NSAID); Drug: Triptan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011 - Condition: Solid Tumors
Interventions: Drug: dalotuzumab; Drug: dalotuzumab; Drug: ridaforolimus
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Solid Tumors
Intervention: Drug: ridaforolimus
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hypertension
Intervention: Drug: Losartan 50 mg / HCTZ 12.5 mg
Sponsors: Merck; Merck
Completed - verified October 2011 - Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MK-4074 200 mg; Drug: Placebo for MK-4074 100 mg; Drug: Pioglitazone hydrochloride 30 mg; Drug: Placebo for pioglitazone hydrochloride 30 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Advanced Solid Tumor
Interventions: Drug: MSC2015103B; Drug: MSC2015103B
Sponsors: EMD Serono; EMD Serono
Recruiting - verified March 2012 - Condition: Human Papillomavirus
Intervention: Biological: Gardasil
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Not yet recruiting - verified May 2012 - Conditions: Ovarian Cancer; Uterine Cancer
Interventions: Drug: fosaprepitant; Drug: aprepitant and standard pre-medications
Sponsors: Gynecologic Oncology Associates; Gynecologic Oncology Associates; Merck
Active, not recruiting - verified November 2011 - Condition: Osteoarthritis
Interventions: Drug: Etoricoxib; Drug: Placebo for etoricoxib
Sponsors: Merck; Merck
Withdrawn - verified December 2011 - Conditions: Non-Small Cell Lung Cancer; Multiple Myeloma
Interventions: Biological: L-BLP25; Other: No intervention
Sponsors: Merck KGaA; Merck KGaA
Enrolling by invitation - verified February 2012 - Condition: Meningococcal Meningitis
Interventions: Biological: placebo+ Combined Tetanus, Reduced Diphtheria Toxoid Acellular Pertussis Vaccine+Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY Conjugate Vaccine+Combined Tetanus, Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine +Quadrivalent Human Papillomavirus Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Adult Subjects Undergoing Abdominal Surgery Under General Anesthesia
Interventions: Drug: sugammadex; Drug: placebo
Sponsors: Central Clinical Hospital #1 of LLC Russian Railways; Central Clinical Hospital #1 of LLC Russian Railways
Not yet recruiting - verified August 2011 - Condition: Implantation, Embryo
Interventions: Drug: Leuprolide; Drug: Ganirelix
Sponsors: Kelly, Maureen, M.D.; Kelly, Maureen, M.D.; Merck
Recruiting - verified August 2011 - Conditions: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation; Antithrombotic Agents
Interventions: Drug: Sugammadex; Drug: neostigmine and glycopyrrolate or atropine; Drug: Placebo
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Infertility
Intervention:
Sponsors: Merck KGaA; Merck KGaA; Merck Ltd.
Recruiting - verified February 2012 - Condition: Infertility
Interventions: Drug: HCG; Drug: Lupron Trigger; Drug: Dual Trigger
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Merck
Not yet recruiting - verified October 2011 - Condition: Fertility
Intervention: Procedure: Freezing
Sponsors: Main Line Fertility Center; Main Line Fertility Center; Merck
Recruiting - verified August 2011 - Conditions: Human Immunodeficiency Virus; Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); Merck; ViiV Healthcare
Recruiting - verified April 2012 - Condition: Dyslipidemia
Interventions: Drug: ERN/LRPT; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Condyloma; Genital Warts
Intervention:
Sponsors: Karolinska Institutet; Lisen Arnheim Dahlstrom; Merck
Completed - verified March 2012 - Condition: Human Papillomavirus
Intervention:
Sponsors: The Alfred; The Alfred; Merck
Recruiting - verified August 2011 - Conditions: Cytokine Environment; Kinetics of Bone Cells Differentiation and Activity in Untreated RA and AS Patients.
Intervention:
Sponsors: Instituto de Medicina Molecular; Instituto de Medicina Molecular; Merck
Not yet recruiting - verified December 2011 - Conditions: Crohn's Disease; Ulcerative Colitis
Intervention:
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School; Merck
Recruiting - verified August 2011 - Conditions: Dyslipidemia; Hypercholesterolemia
Intervention:
Sponsors: Merck; Merck
Active, not recruiting - verified September 2011 - Conditions: Lung Transplant Infection; Receiving Posaconazole
Intervention: Other: collection of blood samples for PK testing
Sponsors: University of Pittsburgh; University of Pittsburgh; Merck
Not yet recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Intervention:
Sponsors: Merck; Merck
Completed - verified December 2011 - Conditions: Nausea; Vomiting
Interventions: Drug: fosaprepitant dimeglumine; Drug: 5HT3 RA; Drug: dexamethasone
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck Kft., Hungary
Not yet recruiting - verified March 2012 - Condition: Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Intervention: Drug: zolinza/vorinostat
Sponsors: National Center for Tumor Diseases, Heidelberg; National Center for Tumor Diseases, Heidelberg; University Hospital Heidelberg; Merck
Recruiting - verified May 2012 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck spol. s r.o., Slovakia
Recruiting - verified January 2012 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck spol.s.r.o., Czech Republic
Recruiting - verified December 2011 - Conditions: Chronic Renal Insufficiency; Type 2 Diabetes Mellitus
Intervention: Drug: MK-3102
Sponsors: Merck; Merck
Completed - verified April 2012 - Condition: Migraine
Intervention:
Sponsors: Merck; Merck
Active, not recruiting - verified February 2012 - Condition: Glucose Intolerance
Interventions: Drug: Sitagliptin 25 mg; Drug: Sitagliptin 50 mg; Drug: Placebo for Sitagliptin 25 mg; Drug: Placebo for Sitagliptin 50 mg
Sponsors: Merck; Merck
Completed - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: vaniprevir; Drug: vaniprevir; Biological: peg-IFN alfa-2b; Drug: ribavirin
Sponsors: Merck; Merck
Active, not recruiting - verified March 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Vaniprevir; Biological: peg-IFN alfa-2b; Drug: ribavirin
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Conditions: Platelet Aggregation Inhibitors; Incretins
Intervention: Other: venous puncture
Sponsors: National Council of Scientific and Technical Research, Argentina; National Council of Scientific and Technical Research, Argentina; Merck
Not yet recruiting - verified August 2011 - Condition: Children Born With Serious Intra-uterine Growth Retardation
Interventions: Drug: Saizen; Drug: Saizen
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Completed - verified July 2011 - Condition: Candidemia
Intervention:
Sponsors: University of Turin, Italy; University of Turin, Italy; Merck
Recruiting - verified January 2011 - Condition: Asthma
Interventions: Drug: inhaled corticosteroid/β2 agonist Monotherapy; Drug: Inhaled corticosteroid/β2 agonist Combination Therapy
Sponsors: The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University; Merck
Active, not recruiting - verified February 2012 - Conditions: Stable Angina; Coronary Disease
Interventions: Drug: Nicorandil; Drug: basic treatment
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Co., Ltd., China
Recruiting - verified January 2012 - Condition: Chronic Hepatitis C
Intervention: Drug: PEG IFN/Ribavirin
Sponsors: University of Modena and Reggio Emilia; Prof. Facchinetti Fabio; Merck
Completed - verified October 2011 - Condition: Rheumatoid Arthritis
Interventions: Biological: MK-8808 500 mg/m^2; Biological: Rituximab 500 mg/m^2; Drug: Methotrexate; Biological: MabThera (rituximab) 500 mg/m^2; Biological: Rituxan (rituximab) 500 mg/m^2; Biological: MK-8808 1000 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Recruiting - verified March 2012 - Conditions: Culture Media; DNA
Intervention:
Sponsors: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Merck Serono S.A., Geneva
Recruiting - verified July 2011 - Condition: Hypertension
Intervention:
Sponsors: Merck; Merck
Completed - verified August 2011 - Condition: Bacteremia
Intervention:
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Merck
Not yet recruiting - verified January 2011 - Condition: Vaginosis, Bacterial
Intervention: Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Sponsors: Eastern Virginia Medical School; Eastern Virginia Medical School; Merck
Recruiting - verified April 2012 - Condition: Gastric Cancer
Intervention: Drug: Cetuximab and Chemotherapy (cisplatin + TS-1)
Sponsors: Merck KGaA; Merck KGaA
Active, not recruiting - verified January 2012 - Conditions: Anogenital Warts; HIV
Intervention:
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Espacio Comun; Universidad Peruana Cayetano Heredia
Recruiting - verified April 2012 - Condition: Herpes Zoster
Interventions: Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous; Biological: ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous; Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal; Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal; Biological: Full Dose Intradermal Placebo; Biological: Intradermal Placebo
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Condition: Migraine Disorders
Interventions: Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Triptan monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011 - Condition: Migraine Disorders
Interventions: Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Single-entity oral triptans
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011 - Conditions: HIV-1 Infected Patients; Fold-change Resistance; Resistance Mutations
Intervention:
Sponsors: Università Vita-Salute San Raffaele; Università Vita-Salute San Raffaele; IRCCS San Raffaele; Merck
Not yet recruiting - verified June 2011 - Condition: Growth Disorders
Intervention: Device: easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck, S.L., Spain
Not yet recruiting - verified January 2012 - Condition: Phenylketonuria (PKU)
Interventions: Drug: Kuvan®; Other: Phe-restricted diet
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified March 2012 - Condition: Allergic Rhinitis
Interventions: Drug: epinastine 0.1%; Drug: epinastine 0.1% with taste masking agent; Drug: epinastine 0.2%; Drug: epinastine 0.2% with taste masking agent; Drug: azelastine 0.1%
Sponsors: Merck; Merck
Completed - verified June 2011 - Condition: Interstitial Lung Disease
Interventions: Drug: INS316 solution for inhalation; Drug: hypertonic saline 3% sodium chloride solution
Sponsors: Merck; Merck
Terminated - verified June 2011 - Condition: Hypercholesterolemia
Intervention: Drug: Ezetimibe
Sponsors: Merck; Merck
Completed - verified February 2012 - Condition: Photorefractive Keratectomy
Interventions: Drug: diquafosol tetrasodium ophthalmic solution 2%; Drug: placebo
Sponsors: Merck; Merck
Terminated - verified June 2011 - Condition: Menstrual Problem
Intervention: Drug: Marvelon
Sponsors: Family Planning Association New South Wales; Family Planning Association New South Wales; Merck
Not yet recruiting - verified June 2011 - Conditions: Diabetes; Hypothyroidism
Intervention: Drug: Euthyrox (levothyroxine)
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Condition: Cancer, Advanced
Intervention: Drug: ridaforolimus
Sponsors: Merck; Merck
Completed - verified May 2012 - Condition: Cervical Cancer
Intervention:
Sponsors: University Hospital for Infectious Diseases, Croatia; University Hospital for Infectious Diseases, Croatia; Merck
Recruiting - verified June 2011 - Condition: Colorectal Cancer Metastatic
Intervention: Drug: Cetuximab
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus; Merck KGaA
Not yet recruiting - verified June 2011 - Condition: Renal Impairment
Intervention: Drug: 50mg safinamide
Sponsors: Merck KGaA; Merck KGaA
Completed - verified October 2011 - Condition: Advanced Solid Tumor
Intervention: Drug: MEK inhibitor MSC1936369B and Temsirolimus
Sponsors: EMD Serono; EMD Serono
Recruiting - verified April 2012 - Condition: Multiple Myeloma in Relapse
Interventions: Drug: Vorinostat; Drug: Bortezomib; Drug: Doxorubicin; Drug: Dexamethasone
Sponsors: University Hospital Freiburg; University Hospital Freiburg; Merck; Janssen-Cilag Ltd.
Recruiting - verified September 2011 - Condition: Scleroderma
Intervention: Drug: Cuprimine (penicillamine)
Sponsors: Merck; Merck
No longer available - verified June 2011 - Conditions: Pyelonephritis; Infections, Urinary Tract
Interventions: Drug: GSK2251052; Drug: imipenem-cilastatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Suspended - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Oxyntomodulin (Treatment A); Drug: Liraglutide 0.6 mg (Treatment B); Drug: Liraglutide 1.2 mg (Treatment C); Drug: Placebo for Oxyntomodulin (Treatment D)
Sponsors: Merck; Merck
Completed - verified December 2011 - Condition: Infection; Diabetic Foot
Interventions: Drug: Ertapenem sodium; Drug: Piperacillin/tazobactam sodium; Drug: Piperacillin/tazobactam-matching placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Osteoarthritis; Chronic Pain
Intervention: Drug: duloxetine, diclofenac
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Research Resources (NCRR); Merck; Nuvo Research Inc.
Recruiting - verified March 2012 - Condition: Acinetobacter Bacteraemia
Intervention:
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan; Merck
Not yet recruiting - verified June 2011 - Condition: Alzheimer's Disease
Intervention: Radiation: [18F]MK-3328
Sponsors: Merck; Merck
Active, not recruiting - verified May 2012 - Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Ezetimibe; Drug: Ezetimibe/atorvastatin; Drug: Placebo to atorvastatin; Drug: Placebo to ezetimibe; Drug: Placebo to ezetimibe/atorvastatin
Sponsors: Merck; Merck
Active, not recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: MK-1029; Drug: Placebo for MK-1029
Sponsors: Merck; Merck
Completed - verified April 2012 - Condition: Atrial Fibrillation
Intervention: Drug: Vernakalant
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: vaniprevir; Drug: vaniprevir; Drug: Placebo to vaniprevir; Biological: peg-IFN alfa-2b; Drug: ribavirin
Sponsors: Merck; Merck
Active, not recruiting - verified April 2012 - Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Ezetimibe; Drug: Ezetimibe/atorvastatin; Drug: Placebo to atorvastatin; Drug: Placebo to ezetimibe; Drug: Placebo to ezetimibe/atorvastatin
Sponsors: Merck; Merck
Completed - verified May 2012 - Condition: Hypertension
Interventions: Drug: MK-7145; Drug: MK-7145; Drug: Hydrochlorothiazide (HCTZ); Drug: Placebo to MK-7145; Drug: Placebo to HCTZ
Sponsors: Merck; Merck
Completed - verified February 2012 - Condition: Growth Disorders
Intervention: Device: Easypod™
Sponsors: Merck KGaA; Merck KGaA; Merck A.E., Greece
Not yet recruiting - verified January 2012 - Condition: Nasal Polyps
Interventions: Drug: Mometasone Furoate Nasal Spray (MFNS); Drug: Placebo for MFNS
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: Gavindo®; Drug: Pregabaline
Sponsors: Merck KGaA; Merck KGaA; Merck S.A. de C.V., Mexico
Recruiting - verified January 2012 - Condition: Hypertension
Intervention:
Sponsors: Merck; Merck
Completed - verified August 2011 - Condition: Homonymous Hemianopia
Intervention:
Sponsors: University Hospital Tuebingen; University Hospital Tuebingen; Merck
Recruiting - verified April 2011 - Condition: Thrombosis
Interventions: Drug: dabigatran etexilate; Drug: rivaroxaban
Sponsors: Merck; Merck
Completed - verified February 2012 - Condition: Chemotherapy Induced Nausea and Vomiting
Interventions: Drug: Aprepitant 125 mg; Drug: Aprepitant 80 mg; Drug: Aprepitant PFS; Drug: Ondansteron; Drug: Placebo for Aprepitant 125 mg; Drug: Placebo for Aprepitant 80 mg; Drug: Placebo for Aprepitant PFS
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Osteoporosis
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Merck
Recruiting - verified May 2012 - Condition: HIV Positive
Intervention: Drug: Vorinostat
Sponsors: Bayside Health; Bayside Health; Merck
Recruiting - verified June 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: Pegylated interferon alfa 2b; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute; Merck
Not yet recruiting - verified May 2011 - Conditions: Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC); Crohn's Disease (CD); Anal Human Papillomavirus
Intervention: Procedure: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Sponsors: University of Pittsburgh; University of Pittsburgh; Merck
Recruiting - verified January 2012
 |
Merck - Database of Clinical Trials by Pharmaceutical Companies |
